Online citations, reference lists, and bibliographies.
← Back to Search

'On‐off' Phenomenon In Parkinson's Disease

T. Eriksson, A. Granérus, A. Linde, A. Carlsson
Published 1988 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
Administration of a low-protein diet to parkinsonian patients with “on-off” syndromes consistently increased the total daily time of “on” states when compared with a high-protein diet. The clinical effect of the low-protein diet may be due to a marked decrease in the plasma concentration of large neutral amino acids that compete with L-dopa for carrier-mediated transport into the brain.
This paper references
10.1016/S0140-6736(73)91718-2
Sustained-release levodopa.
A. Woods (1973)
Sustained-release levodopa. Lancet 1973;1:1391
AC Woods (1973)
10.1212/WNL.24.5.431
“On‐off” phenomenon with levodopa therapy in parkinsonism
S. Fahn (1974)
10.1212/WNL.24.10.953
Plasma dopa concentrations and the “on‐off” effect after chronic treatment of Parkinson's disease
R. Sweet (1974)
The clinical physiology of side effects in long-term L-DOPA therapy.
A. Barbeau (1974)
Variations in the "on-off" effect.
M. Yahr (1974)
The "on-off" response to chronic L-DOPA treatment of Parkinsonism.
R. Sweet (1974)
Variations in the “on-off
Yahr (1974)
10.1056/NEJM197501232920404
Protein intake and treatment of Parkinson's disease with levodopa.
I. Mena (1975)
Patterns of clinical reaponse and plaema dopa levels in Parkinson’s disease
ES Toloea (1975)
10.1002/ANA.410020207
Levodopa‐Induced dopamine receptor hypersensitivity
Harold L. Klawans (1977)
Regulation of amino acid availability to the brain
W. Pardridge (1977)
10.1016/0024-3205(78)90575-1
GABA receptor binding in the parkinsonian brain.
U. Rinne (1978)
10.1111/J.0954-6820.1978.TB14835.X
Factors influencing the occurrence of "on-off" symptoms during long-term treatment with L-dopa.
A. Granérus (1978)
10.1038/273059A0
Receptor basis for dopaminergic supersensitivity in Parkinson's disease
T. Lee (1978)
Hornykiewicz 0. Receptor basis for dopaminergic supersensitivity in Parkinson's dieeaee
T Lee (1978)
10.1111/j.1471-4159.1979.tb04523.x
BRAIN TISSUE AND PLASMA ASSAY OF L‐DOPA AND α‐METHYLDOPA METABOLITES BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY WITH ELECTROCHEMICAL DETECTION
C. Freed (1979)
Parkinson's disease: current progress, problems and management
C D Maraden (1980)
On-off’ phenomena in Parkinson’s dieeaee
CD Maraden (1980)
10.1016/0014-2999(82)90626-4
Behavioural and biochemical changes following chronic administration of L-dopa to rats.
C. Pycock (1982)
10.1152/PHYSREV.1983.63.2.484
Role of precursor availability in control of monoamine biosynthesis in brain.
J. Fernstrom (1983)
Are "on-off" effects during chronic L-dopa treatment due to faulty feedback control of the nigrostriatal dopamine pathway?
A. Carlsson (1983)
10.1111/j.1600-0404.1983.tb01513.x
Problems associated with long‐term levodopa treatment of Parkinson's disease
U. Rinne (1983)
10.1016/0166-2236(83)90003-6
‘On—off’ effects: the new challenge in parkinsonism
P. Lewitt (1983)



This paper is referenced by
10.3390/ph14080821
Exploring the Role of Nutraceuticals in Major Depressive Disorder (MDD): Rationale, State of the Art and Future Prospects
M. A. Alvarez-Mon (2021)
10.3389/FNEUR.2019.01087
Contributions of Gut Bacteria and Diet to Drug Pharmacokinetics in the Treatment of Parkinson's Disease
S. V. Kessel (2019)
10.1111/jvp.12230
Nanoemulsion formulation of florfenicol improves bioavailability in pigs.
Q. Zhang (2016)
10.1186/s40734-016-0036-9
Motor fluctuations due to interaction between dietary protein and levodopa in Parkinson’s disease
T. Virmani (2016)
10.1111/1747-0080.12118
Current practice in nutrition diagnosis and intervention for the management of Parkinson's disease in Australia and Canada
J. Sheard (2015)
10.1002/adhm.201500416
Application of monodirectional Janus patch to oromucosal delivery system.
J. B. You (2015)
10.1016/B978-0-12-411462-3.00043-6
A Plant-Food Diet in the Risk and Management of Parkinson’s Disease
Luciana Baroni (2015)
10.3329/JOM.V14I2.19670
Trends in Managing Parkinson’s Disease - A Review
Sm Rashid Hilaly (2014)
10.2147/JPRLS.S49186
Ensuring good nutritional status in patients with Parkinson's disease: challenges and solutions
L. Baroni (2014)
Characterisation of embryonic ventral mesencephalon grafts in a rat model of Parkinson’s disease
M. Fjodorova (2013)
10.1021/jf3052708
Pharmacokinetic characteristics of capsaicin-loaded nanoemulsions fabricated with alginate and chitosan.
A. Choi (2013)
10.1016/j.pmrj.2011.11.008
Neuroleptic Malignant Syndrome Associated With the Use of Carbidopa/Levodopa for Dystonia in Persons With Cerebral Palsy
D. Perry (2012)
10.1016/B978-84-458-1911-1.50017-8
Enfermedad de Parkinson
L. Toledo (2012)
10.2165/00003495-200262100-00005
Food-Drug Interactions
L. Schmidt (2012)
10.1002/mds.23226
Low‐protein and protein‐redistribution diets for Parkinson's disease patients with motor fluctuations: A systematic review
E. Cereda (2010)
10.1109/CCA.2010.5611215
Dynamic models with quantized output for modeling patient response to pharmacotherapy
M. Bjork (2010)
10.1007/978-1-60327-362-6_22
Drug–Nutrient Interactions in the Elderly
B. Kinosian (2009)
10.1007/978-1-60327-362-6_9
Effects of Specific Foods and Dietary Components on Drug Metabolism
K. Anderson (2009)
10.1016/j.ejps.2009.09.019
Pharmacokinetic evaluation and modeling of formulated levodopa intranasal delivery systems.
Tae Kyung Kim (2009)
Efeito de uma Intervenção Nutricional em Doentes de Parkinson submetidos a Cirurgia de Estimulação Cerebral Profunda Effect of a Nutritional Intervention on Parkinson's Disease Patients after Deep Brain Stimulation Surgery
Eduarda Filipa (2008)
10.1002/mds.22169
Effects of a NR2B selective NMDA glutamate antagonist, CP‐101,606, on dyskinesia and parkinsonism
John G. Nutt (2008)
10.1517/14656566.8.5.657
Duodenal levodopa infusion for the treatment of Parkinson’s disease
J. Samanta (2007)
10.21236/ada473438
Literature-Related Discovery (LRD)
R. Kostoff (2007)
10.1016/j.brainresbull.2007.05.005
Movement patterns of peak-dose levodopa-induced dyskinesias in patients with Parkinson's disease
Jackie Gour (2007)
10.1016/S0072-9752(06)80054-0
Chapter 50 Pain in Parkinson's disease.
G. Wasner (2006)
10.1159/000091825
Food Habits and Intake of Nutrients in Elderly Patients with Parkinson’s Disease
B. Lorefält (2006)
10.1517/14656566.7.10.1399
The levodopa wearing-off phenomenon in Parkinson’s disease: pharmacokinetic considerations
F. Stocchi (2006)
The impact of drug-induced dyskinesias on rapid alternating movements in patients with Parkinson's disease
M. Ghassemi (2005)
10.1517/17425247.2.6.1059
Advances in the delivery of treatments for Parkinson’s disease
T. Johnston (2005)
10.1002/mds.20462
Other pharmacological treatments for motor complications and dyskinesias
C. Waters (2005)
Ambulatory accelerometry in Parkinson's disease
J. Hoff (2005)
10.3305/NUTR
Interacciones entre los alimentos y las estatinas
S. D. Andrés (2004)
See more
Semantic Scholar Logo Some data provided by SemanticScholar